BRPI0607198A2 - composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica - Google Patents
composição, uso da composição método de tratamento doenças, e, embalagem farmacêuticaInfo
- Publication number
- BRPI0607198A2 BRPI0607198A2 BRPI0607198A BRPI0607198A BRPI0607198A2 BR PI0607198 A2 BRPI0607198 A2 BR PI0607198A2 BR PI0607198 A BRPI0607198 A BR PI0607198A BR PI0607198 A BRPI0607198 A BR PI0607198A BR PI0607198 A2 BRPI0607198 A2 BR PI0607198A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- treatment method
- pharmaceutical packaging
- diseases treatment
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65288905P | 2005-02-15 | 2005-02-15 | |
| PCT/US2006/006991 WO2006089312A2 (en) | 2005-02-15 | 2006-02-13 | Orally bioavailable cci-779 tablet formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0607198A2 true BRPI0607198A2 (pt) | 2016-11-01 |
Family
ID=36763299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607198A BRPI0607198A2 (pt) | 2005-02-15 | 2006-02-13 | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20060183766A1 (pt) |
| EP (1) | EP1855656A2 (pt) |
| JP (1) | JP2008530145A (pt) |
| KR (1) | KR20070104908A (pt) |
| CN (1) | CN101119709A (pt) |
| AU (1) | AU2006214021A1 (pt) |
| BR (1) | BRPI0607198A2 (pt) |
| CA (1) | CA2596392A1 (pt) |
| CR (1) | CR9262A (pt) |
| IL (1) | IL184716A0 (pt) |
| MX (1) | MX2007009812A (pt) |
| NI (1) | NI200700207A (pt) |
| NO (1) | NO20073786L (pt) |
| RU (1) | RU2007127499A (pt) |
| WO (1) | WO2006089312A2 (pt) |
| ZA (1) | ZA200706758B (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| RU2344821C2 (ru) * | 2002-07-30 | 2009-01-27 | Уайт | Парентеральные композиции, содержащие гидроксиэфиры рапамицина |
| DE602004011398T2 (de) * | 2004-01-08 | 2009-01-15 | Wyeth | Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 |
| JP2008530145A (ja) * | 2005-02-15 | 2008-08-07 | ワイス | 経口投与可能なｃｃｉ−７７９製剤 |
| AU2006315512B2 (en) * | 2005-11-14 | 2012-11-01 | Ariad Pharmaceuticals, Inc. | Administration of an mTOR inhibitor to treat patients with cancer |
| CA2669415A1 (en) | 2006-11-14 | 2008-05-22 | Ariad Pharmaceuticals, Inc. | Solid dosage form comprising ap23573 |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| GB2475701B (en) * | 2009-11-26 | 2011-10-19 | Michael Hilary Burke | A process for the preparation of an orally administered anthelmintic unit dose tablet |
| WO2011151704A2 (en) | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
| AU2012362562B2 (en) | 2011-12-27 | 2017-11-02 | Amgen (Europe) GmbH | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| HUP1400075A2 (hu) * | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| MA43402A (fr) * | 2015-12-08 | 2018-10-17 | Ardea Biosciences Inc | Composition pharmaceutique comprenant un inhibiteur puissant d'urat1 |
| WO2017129772A1 (en) | 2016-01-29 | 2017-08-03 | Xellia Phamaceuticals Aps | Stable pharmaceutical compositions of temsirolimus |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| DE69736750T2 (de) * | 1996-07-30 | 2007-08-16 | Novartis Ag | Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände |
| RU2186562C2 (ru) * | 1996-08-22 | 2002-08-10 | Ресеч Трайангл Фармасьютикалс Лтд. | Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления |
| US6015815A (en) * | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| RU2344821C2 (ru) * | 2002-07-30 | 2009-01-27 | Уайт | Парентеральные композиции, содержащие гидроксиэфиры рапамицина |
| UA81265C2 (en) * | 2002-09-17 | 2007-12-25 | Wyeth Corp | Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof |
| EP1646635A1 (en) * | 2003-07-16 | 2006-04-19 | Wyeth | Cci-779 isomer c |
| DE602004011398T2 (de) * | 2004-01-08 | 2009-01-15 | Wyeth | Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 |
| JP2008530145A (ja) * | 2005-02-15 | 2008-08-07 | ワイス | 経口投与可能なｃｃｉ−７７９製剤 |
-
2006
- 2006-02-13 JP JP2007555397A patent/JP2008530145A/ja not_active Withdrawn
- 2006-02-13 US US11/352,726 patent/US20060183766A1/en not_active Abandoned
- 2006-02-13 CA CA002596392A patent/CA2596392A1/en not_active Abandoned
- 2006-02-13 BR BRPI0607198A patent/BRPI0607198A2/pt not_active IP Right Cessation
- 2006-02-13 EP EP06736333A patent/EP1855656A2/en not_active Withdrawn
- 2006-02-13 CN CNA2006800049859A patent/CN101119709A/zh not_active Withdrawn
- 2006-02-13 AU AU2006214021A patent/AU2006214021A1/en not_active Abandoned
- 2006-02-13 KR KR1020077018391A patent/KR20070104908A/ko not_active Withdrawn
- 2006-02-13 WO PCT/US2006/006991 patent/WO2006089312A2/en not_active Ceased
- 2006-02-13 MX MX2007009812A patent/MX2007009812A/es unknown
- 2006-02-13 RU RU2007127499/15A patent/RU2007127499A/ru not_active Application Discontinuation
-
2007
- 2007-07-19 IL IL184716A patent/IL184716A0/en unknown
- 2007-07-20 NO NO20073786A patent/NO20073786L/no not_active Application Discontinuation
- 2007-07-20 CR CR9262A patent/CR9262A/es not_active Application Discontinuation
- 2007-08-14 ZA ZA200706758A patent/ZA200706758B/xx unknown
- 2007-08-14 NI NI200700207A patent/NI200700207A/es unknown
-
2008
- 2008-03-12 US US12/075,520 patent/US20080161336A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL184716A0 (en) | 2008-12-29 |
| JP2008530145A (ja) | 2008-08-07 |
| WO2006089312A2 (en) | 2006-08-24 |
| NI200700207A (es) | 2008-07-24 |
| CN101119709A (zh) | 2008-02-06 |
| US20060183766A1 (en) | 2006-08-17 |
| MX2007009812A (es) | 2007-10-23 |
| WO2006089312A3 (en) | 2006-10-19 |
| CA2596392A1 (en) | 2006-08-24 |
| EP1855656A2 (en) | 2007-11-21 |
| AU2006214021A1 (en) | 2006-08-24 |
| NO20073786L (no) | 2007-09-03 |
| US20080161336A1 (en) | 2008-07-03 |
| KR20070104908A (ko) | 2007-10-29 |
| ZA200706758B (en) | 2010-01-27 |
| RU2007127499A (ru) | 2009-03-27 |
| CR9262A (es) | 2007-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0820568A2 (pt) | Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal | |
| BRPI0916235A2 (pt) | composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv | |
| IL184652A (en) | Topical pharmaceutical composition comprising imiquimod, a packaged composition comprising it and methods of sterilizing same | |
| IL195491A (en) | Pharmaceutical compositions of tmc278 and processes for their preparation | |
| EP1962961A4 (en) | DEMIKÖRPER: DIMERIZATION-ACTIVATED THERAPEUTIC AGENT | |
| EP1824442A4 (en) | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FROM THE GARCINIA MANGOSTANA L PLANT | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BRPI0813897A2 (pt) | Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, seqüência de nucleotídeos. | |
| MA29017B1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| FR2872813B1 (fr) | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| MA28575B1 (fr) | Derives de la 1-amino-phthalazine, leur preparation , et leur application en therapeutique | |
| FR2910473B1 (fr) | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. | |
| FR2904316B1 (fr) | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. | |
| CL2007002376A1 (es) | Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas. | |
| FR2903985B1 (fr) | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique | |
| FR2866888B1 (fr) | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique | |
| DE602005005456D1 (de) | Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen | |
| FR2882054B1 (fr) | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
| BRPI0720323A2 (pt) | composto, método de tratamento, composição farmacêutica e uso do composto | |
| FR2866885B1 (fr) | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique | |
| FR2865205B1 (fr) | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique | |
| IL194880A (en) | Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them | |
| FR2888847B1 (fr) | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique | |
| FR2891828B1 (fr) | Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique | |
| FR2888848B1 (fr) | Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
| B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO 20070113335 DE 14/08/2007 |
|
| B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: O DESPACHO 11.6.1 DA RPI 2146 DE 22/02/2012 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO 6.7 DA RPI 2100 DE 05/04/2011 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |